Trials / Completed
CompletedNCT00245947
Study Evaluating ERB-041 in Active Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERB-041 |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-10-28
- Last updated
- 2009-09-10
Source: ClinicalTrials.gov record NCT00245947. Inclusion in this directory is not an endorsement.